Found 1 Presentation For Request "1014TiP"
1014TiP - PROOF: A multicenter, open-label, randomized, phase III trial of infigratinib vs gemcitabine + cisplatin in patients with advanced cholangiocarcinoma with FGFR2 gene rearrangements
- Ghassan K. Abou-Alfa (New York, NY, United States of America)
Abstract
Background
Cholangiocarcinoma (CCA) treatment options are limited with a need to provide better disease control, improved outcome, and targeted therapy that is less toxic than standard chemotherapy. As the understanding of the molecular landscape of CCA has increased, the fibroblast growth factor receptor (FGFR) family has been found to play an important role in CCA.
Trial design
Patients with advanced/metastatic or inoperable CCA with
Clinical trial identification
NCT03773302.
Editorial acknowledgement
Lee Miller (Miller Medical Communications).
Legal entity responsible for the study
QED Therapeutics Inc.
Funding
QED Therapeutics Inc.
Disclosure
G.K. Abou-Alfa: Advisory/Consultancy, Research grant/Funding (institution): Agios; Advisory/Consultancy, Research grant/Funding (institution): AstraZeneca; Advisory/Consultancy, Research grant/Funding (institution): Bayer; Advisory/Consultancy, Research grant/Funding (institution): BeiGene; Advisory/Consultancy: BiolineRx; Advisory/Consultancy, Research grant/Funding (institution): Bristol-Myers Squibb; Advisory/Consultancy, Research grant/Funding (institution): Celgene; Advisory/Consultancy: Debiopharm Group; Advisory/Consultancy: Eisai; Advisory/Consultancy, Research grant/Funding (institution): Exelixis; Advisory/Consultancy: Flatiron Health; Advisory/Consultancy: Genoscience Pharma; Advisory/Consultancy: Gilead Sciences; Advisory/Consultancy: Ipsen; Advisory/Consultancy: LAM Therapeutics; Advisory/Consultancy, Research grant/Funding (institution): Lilly; Advisory/Consultancy: Merck Serono; Advisory/Consultancy: Minapharma; Advisory/Consultancy, Research grant/Funding (institution): QED Therapeutics; Advisory/Consultancy: RedHill Biopharma; Advisory/Consultancy, Research grant/Funding (institution): Roche; Advisory/Consultancy: Sanofi; Advisory/Consultancy: Sillajen; Advisory/Consultancy: twoXAR; Advisory/Consultancy: Vicus Therapeutics; Advisory/Consultancy: Yiviva; Research grant/Funding (institution): Acta Biologica; Research grant/Funding (institution): Array BioPharma; Research grant/Funding (institution): CASI Pharmaceuticals; Research grant/Funding (institution): Genentech. I. Borbath: Advisory/Consultancy, Research grant/Funding (institution): Novartis; Research grant/Funding (institution): Celgene; Research grant/Funding (institution): Ipsen. A. Lamarca: Honoraria (self), Travel/Accommodation/Expenses, educational support: Bayer; Honoraria (self), Advisory/Consultancy, Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses, Knowledge Network and NETConnect Initiatives funding: Ipsen; Honoraria (self), Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses, educational support: Pfizer; Advisory/Consultancy: Eisai; Advisory/Consultancy: Nutricia; Advisory/Consultancy: QED Therapeutics; Advisory/Consultancy: Roche; Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: AAA; Speaker Bureau/Expert testimony: Incyte; Speaker Bureau/Expert testimony: Merck; Travel/Accommodation/Expenses: Delcath; Travel/Accommodation/Expenses: Mylan; Travel/Accommodation/Expenses: Novartis; Travel/Accommodation/Expenses: SirtExand. T. Macarulla: Advisory/Consultancy: Baxalta; Advisory/Consultancy: Baxter; Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: Celgene; Advisory/Consultancy: Incyte; Advisory/Consultancy: Ipsen; Advisory/Consultancy, Research grant/Funding (institution): Lilly; Advisory/Consultancy: QED Therapeutics; Advisory/Consultancy, Research grant/Funding (institution): Roche; Advisory/Consultancy, Travel/Accommodation/Expenses: Sanofi/Aventis; Advisory/Consultancy, Travel/Accommodation/Expenses: SERVIER; Advisory/Consultancy: Shire; Research grant/Funding (institution): Agios; Research grant/Funding (institution): ASLAN Pharmaceuticals; Research grant/Funding (institution): AstraZeneca; Research grant/Funding (institution): Bayer; Research grant/Funding (institution): Genentech; Research grant/Funding (institution): Halozyme; Research grant/Funding (institution): Immunomedics; Research grant/Funding (institution): Merrimack; Research grant/Funding (institution): Millennium; Research grant/Funding (institution): Novartis; Research grant/Funding (institution): Novocure; Research grant/Funding (institution): Pfizer S.L.U; Research grant/Funding (institution): Pharmacyclics; Travel/Accommodation/Expenses: H3 Biomedicine; Travel/Accommodation/Expenses: Merck. D-Y. Oh: Advisory/Consultancy: ASLAN; Advisory/Consultancy, Research grant/Funding (self): AstraZeneca; Advisory/Consultancy: Bayer; Advisory/Consultancy: Celgene; Advisory/Consultancy: Genentech/Roche; Advisory/Consultancy: Halozyme; Advisory/Consultancy: Merck Serono; Advisory/Consultancy, Research grant/Funding (self): Novartis; Advisory/Consultancy: Taiho; Advisory/Consultancy: Zymeworks; Research grant/Funding (self): Array; Research grant/Funding (self): Eli Lilly. S. Roychowdhury: Honoraria (self): IDT Integrated DNA Technologies; Advisory/Consultancy: AbbVie, Inc; Advisory/Consultancy: Incyte Corporation; Advisory/Consultancy: QED Therapeutics. R.T. Shroff: Advisory/Consultancy: Agios; Advisory/Consultancy: Clovis; Advisory/Consultancy: Debiopharm; Advisory/Consultancy, Research grant/Funding (institution): Exelixis; Advisory/Consultancy: Incyte; Advisory/Consultancy, Research grant/Funding (institution): Merck; Advisory/Consultancy: QED Therapeutics; Advisory/Consultancy: Seattle Genetics; Research grant/Funding (institution): Haloyzme; Research grant/Funding (institution): Pieris; Research grant/Funding (institution): Rafael Pharmaceuticals; Research grant/Funding (institution): Taiho. M. Howland: Full/Part-time employment: QED Therapeutics Inc. A. Li: Full/Part-time employment: QED Therapeutics Inc. T. Cho: Full/Part-time employment: QED Therapeutics Inc. A. Pande: Full/Part-time employment: QED Therapeutics Inc. M. Javle: Advisory/Consultancy, Research grant/Funding (institution): Incyte; Advisory/Consultancy: Mundipharma EDO GmbH; Advisory/Consultancy: Oncosil; Advisory/Consultancy, Research grant/Funding (institution): QED Therapeutics; Research grant/Funding (institution): Bayer; Research grant/Funding (institution): BeiGene; Research grant/Funding (institution): Merck; Research grant/Funding (institution): Merck Serono; Research grant/Funding (institution): Novartis; Research grant/Funding (institution): Pieris Pharmaceuticals; Research grant/Funding (institution): Rafael Pharmaceuticals; Research grant/Funding (institution): Seattle Genetics. All other authors have declared no conflicts of interest.